Gender differences in cardiometabolic health and disease in a cross-sectional observational obesity study.
Adiponectin
Body fat distribution
Cardiometabolic health
Metabolic syndrome
Sex differences
Journal
Biology of sex differences
ISSN: 2042-6410
Titre abrégé: Biol Sex Differ
Pays: England
ID NLM: 101548963
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
08
08
2021
accepted:
31
01
2022
entrez:
5
3
2022
pubmed:
6
3
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Beyond the degree of adiposity, the pattern of fat distribution has a profound influence on cardiometabolic risk. It is unclear if sex differences in body fat distribution can potentially explain any sex differences in the prevalence of the metabolic syndrome (MetS) and in individual cardiometabolic risk factors among obese men and women. In this cross-sectional analysis, 432 persons from the ongoing Obesity Weight Reduction Study (n = 356 obese, ØBMI 41 ± 8 kg/m In crude analyses, %fat mass and the fat mass/lean mass ratio were significantly higher in women than in men, regardless of increasing obesity categories, from normal weight to grade-3-obesity. In contrast, markers of abdominal obesity, such as waist circumference and waist-to-hip ratio were higher in men than in women, despite similar BMI. The prevalence of the MetS was higher in obese men than in women (67.6 vs. 45.0%, p < 0.0001), particularly in younger individuals < 40 years (72.5 vs. 36.8%, p < 0.0001), but "metabolically healthy obesity" (BMI ≥ 30, no other NCEP ATPIII MetS component) was more common in women than in men (15.6 vs. 4.1%, p < 0.0001). After adjusting for age, %body fat and height, sex differences were observed for HDL-cholesterol (p < 0.001), triglycerides (p < 0.001), fasting glucose (p = 0.002), insulin and HOMA-IR levels (p < 0.001), ALAT (p < 0.001), adiponectin (p < 0.001), and sE-selectin (p = 0.005). In contrast, crude sex differences in other variables, such as leptin levels (68 ± 4 in obese women vs. 33 ± 2 µg/L in men, p < 0.0001), disappeared after accounting for differences in %body fat (least-squares means of leptin: 52 ± 4 vs. 55 ± 6 µg /L, p = 0.740). A logistic regression model adjusting for age and lifestyle factors revealed a lower risk of having MetS for women as compared to men (OR = 0.38[0.22-0.60]). That risk estimate did not materially alter after adding BMI to the model. In contrast, no statistically significant association between sex and MetS prevalence was observed after adding waist circumference and adiponectin to the model (OR = 1.41[0.59-3.36]). Different body fat distribution patterns, particularly abdominal adiposity, adiponectin, and related biomarkers, may contribute to sex differences in cardiometabolic risk factors and to the prevalence of the MetS.
Sections du résumé
BACKGROUND
Beyond the degree of adiposity, the pattern of fat distribution has a profound influence on cardiometabolic risk. It is unclear if sex differences in body fat distribution can potentially explain any sex differences in the prevalence of the metabolic syndrome (MetS) and in individual cardiometabolic risk factors among obese men and women.
METHODS
In this cross-sectional analysis, 432 persons from the ongoing Obesity Weight Reduction Study (n = 356 obese, ØBMI 41 ± 8 kg/m
RESULTS
In crude analyses, %fat mass and the fat mass/lean mass ratio were significantly higher in women than in men, regardless of increasing obesity categories, from normal weight to grade-3-obesity. In contrast, markers of abdominal obesity, such as waist circumference and waist-to-hip ratio were higher in men than in women, despite similar BMI. The prevalence of the MetS was higher in obese men than in women (67.6 vs. 45.0%, p < 0.0001), particularly in younger individuals < 40 years (72.5 vs. 36.8%, p < 0.0001), but "metabolically healthy obesity" (BMI ≥ 30, no other NCEP ATPIII MetS component) was more common in women than in men (15.6 vs. 4.1%, p < 0.0001). After adjusting for age, %body fat and height, sex differences were observed for HDL-cholesterol (p < 0.001), triglycerides (p < 0.001), fasting glucose (p = 0.002), insulin and HOMA-IR levels (p < 0.001), ALAT (p < 0.001), adiponectin (p < 0.001), and sE-selectin (p = 0.005). In contrast, crude sex differences in other variables, such as leptin levels (68 ± 4 in obese women vs. 33 ± 2 µg/L in men, p < 0.0001), disappeared after accounting for differences in %body fat (least-squares means of leptin: 52 ± 4 vs. 55 ± 6 µg /L, p = 0.740). A logistic regression model adjusting for age and lifestyle factors revealed a lower risk of having MetS for women as compared to men (OR = 0.38[0.22-0.60]). That risk estimate did not materially alter after adding BMI to the model. In contrast, no statistically significant association between sex and MetS prevalence was observed after adding waist circumference and adiponectin to the model (OR = 1.41[0.59-3.36]).
CONCLUSIONS
Different body fat distribution patterns, particularly abdominal adiposity, adiponectin, and related biomarkers, may contribute to sex differences in cardiometabolic risk factors and to the prevalence of the MetS.
Identifiants
pubmed: 35246259
doi: 10.1186/s13293-022-00416-4
pii: 10.1186/s13293-022-00416-4
pmc: PMC8897897
doi:
Substances chimiques
Adiponectin
0
Leptin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Informations de copyright
© 2022. The Author(s).
Références
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Obes Rev. 2020 Jul;21(7):e13023
pubmed: 32267621
Appl Physiol Nutr Metab. 2008 Aug;33(4):784-90
pubmed: 18641723
Eur J Clin Nutr. 2010 Jan;64(1):6-15
pubmed: 19738633
PLoS One. 2012;7(4):e33308
pubmed: 22485140
Gend Med. 2012 Feb;9(1):1-8
pubmed: 22333520
Drug Discov Ther. 2015 Dec;9(6):380-5
pubmed: 26781921
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Circulation. 2019 Feb 19;139(8):1025-1035
pubmed: 30779652
Nutrition. 2020 Nov - Dec;79-80:110862
pubmed: 32711387
Endocr Connect. 2017 May;6(4):278-288
pubmed: 28420718
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
Obes Rev. 2009 Mar;10(2):154-67
pubmed: 19021872
Diabetes. 2015 Jul;64(7):2513-25
pubmed: 25677912
Arch Intern Med. 2008 Aug 11;168(15):1609-16
pubmed: 18695074
Biol Sex Differ. 2019 Jul 1;10(1):30
pubmed: 31262349
Endocr Rev. 2016 Jun;37(3):278-316
pubmed: 27159875
Obes Facts. 2017;10(3):207-215
pubmed: 28564650
Int J Equity Health. 2005 Jul 13;4:11
pubmed: 16014164
Hepatology. 2019 Oct;70(4):1457-1469
pubmed: 30924946
JAMA. 2002 Jan 16;287(3):356-9
pubmed: 11790215
Cell Metab. 2018 Aug 7;28(2):256-267.e5
pubmed: 29909969
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Diabetes Care. 2011 Jan;34(1):216-9
pubmed: 20889854
Adipocyte. 2012 Oct 1;1(4):192-199
pubmed: 23700533
Psychosom Med. 2015 Jun;77(5):517-26
pubmed: 25984818
Mol Metab. 2018 Sep;15:3-7
pubmed: 29550349
Ann Ist Super Sanita. 2016 Apr-Jun;52(2):158-66
pubmed: 27364389
Lancet. 2020 Aug 22;396(10250):565-582
pubmed: 32828189
Obesity (Silver Spring). 2012 Oct;20(10):1966-73
pubmed: 22282046
J Am Soc Echocardiogr. 2009 Feb;22(2):107-33
pubmed: 19187853
Diabetes Care. 2002 Aug;25(8):1371-7
pubmed: 12145237
Diabet Med. 2016 Oct;33(10):1366-73
pubmed: 26802741
Clin Nutr. 2014 Aug;33(4):596-602
pubmed: 24315622
JAMA. 2015 May 19;313(19):1973-4
pubmed: 25988468
Eur J Intern Med. 2003 Mar;14(2):101-6
pubmed: 12719027
Diabetol Metab Syndr. 2011 Aug 10;3:18
pubmed: 21831271
Int J Cardiol. 2004 Nov;97(2):257-61
pubmed: 15458693
Int J Obes Relat Metab Disord. 1996 Oct;20(10):904-8
pubmed: 8910093
BMC Geriatr. 2016 Jan 23;16:27
pubmed: 26803469
Obes Res. 2000 Nov;8(8):543-52
pubmed: 11156429
Nutr Metab (Lond). 2010 Apr 07;7:26
pubmed: 20374655
Can J Cardiol. 2016 Dec;32(12):1447-1453
pubmed: 27683172
PLoS One. 2012;7(10):e47791
pubmed: 23082217
Gend Med. 2007;4 Suppl B:S162-77
pubmed: 18156101
Endocr Rev. 2020 May 1;41(3):
pubmed: 32128581
Acta Physiol (Oxf). 2014 Apr;210(4):733-53
pubmed: 24495317
Pharmacol Res. 2017 Jun;120:34-42
pubmed: 28300617
Circulation. 2007 Jul 3;116(1):39-48
pubmed: 17576866
Nutr J. 2006 Dec 22;5:34
pubmed: 17187681
Diabetologia. 2003 Apr;46(4):459-69
pubmed: 12687327
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Nat Rev Endocrinol. 2017 Jun;13(6):352-364
pubmed: 28304393
Biomed Res Int. 2016;2016:3973197
pubmed: 28050556
J Clin Invest. 2019 Oct 1;129(10):3978-3989
pubmed: 31524630
Gend Med. 2009;6 Suppl 1:60-75
pubmed: 19318219
Lancet. 2005 Apr 16-22;365(9468):1398-405
pubmed: 15836888
Public Health Nutr. 2018 Jun;21(9):1693-1703
pubmed: 29506604
Trends Endocrinol Metab. 2016 Dec;27(12):844-855
pubmed: 27640750
J Clin Invest. 2017 Jan 3;127(1):74-82
pubmed: 28045400
Int Heart J. 2015;56(2):196-202
pubmed: 25740581
Diabetologia. 2020 Mar;63(3):453-461
pubmed: 31754750
Int J Environ Res Public Health. 2020 Dec 18;17(24):
pubmed: 33353082